A Study to Evaluate ALN-4915 in Adult Healthy Volunteers

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.

Key facts

Study ID

NCT07535606

Run by

Alnylam Pharmaceuticals

People needed

44

Starts

2026-03-02

Expected to finish

2027-07-31

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Is willing and able to complete all study assessments

You may not qualify if…

• Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >upper limit of normal (ULN)
• Has total bilirubin >ULN
• Has no history of invasive infection by an encapsulated organism
• Has no known complement or immunologic deficiency

Where it is running

• Clinical Trial Site — London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.